Deciphering the multi-state binding and dissociation of fenofibrate with β-cyclodextrin and its derivatives: Insights from phase solubility analysis and molecular modeling

被引：0

作者：

Ai, Fengwei ^{[1
]}

Shen, Wenkang ^{[2
]}

Shen, Quanye ^{[2
]}

Yang, Hangtu ^{[2
]}

Wang, Jiayu ^{[3
]}

Yang, Meng ^{[2
]}

Zhang, Zhiwen ^{[2
]}

Zhang, Ningying ^{[2
]}

Xue, Yunsheng ^{[1
]}

机构：

[1] Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, No. 209, Tongshan Road, Jiangsu, Xuzhou

[2] School of Pharmacy, Xuzhou Medical University, No. 209, Tongshan Road, Jiangsu, Xuzhou

[3] Jiangsu Nhwa Pharmaceutical Co., Ltd, Jiangsu, Xuzhou

来源：

Journal of Molecular Liquids | 2024年 / 415卷

关键词：

Binding–dissociation; Conformational transformations; Fenofibrate inclusion complex; Intermolecular interactions; Thermodynamics analysis;

D O I：

10.1016/j.molliq.2024.126374

中图分类号：

学科分类号：

摘要：

The present study focuses on elucidating the multi-state binding and dissociation interaction of fenofibrate (FNB) with β-cyclodextrin and its derivatives hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutylether-β-cyclodextrin (SBE-β-CD), with a specific emphasis on the correlation between phase solubility analysis and molecular modeling. The dynamic complexation, conformational stability, configuration transition, and binding energy (ΔEbinding) were investigated based on molecular dynamics (MD) simulations. Subsequently, the quantum mechanical calculations were performed to strengthen the MD results. The dissociation of FNB from both rims of the three cyclodextrins (CDs) was examined using umbrella sampling simulations. The FNB molecule was found to bind to CD in a 1:1 stoichiometry with spontaneous and thermodynamic favorability. The binding ability of FNB with three CDs was arranged in the following sequence: SBE-β-CD > HP-β-CD > β-CD. Moreover, the binding conformations in parallel showed a lower ΔEbinding than those in an anti-parallel arrangement. The FNB molecule exhibited an equal probability of dissociating from the primary and secondary cavity orientations of β-CD. In contrast, for HP-β-CD and SBE-β-CD, FNB tended to dissociate from the primary cavity positions. The combination of the phase solubility method with molecular modeling afforded an in-depth and comprehensive understanding of the interactions between FNB and different CDs and has the potential to be generally applicable to the design and optimization of CD carrier materials to enhance the water solubility of poorly soluble compounds. © 2024 Elsevier B.V.

引用

共 85 条

[1] Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-C., Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism, Circulation, 98, pp. 2088-2093, (1998)
[2] Jadwiga N., Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation, Clin. Ther., 24, pp. 2022-2050, (2002)
[3] Lalloyer F., Staels B., Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors, Arterioscler. Thromb. Vasc. Biol., 30, pp. 894-899, (2010)
[4] Gunwal D., Dutt B., Choudhary M., Budhwar V., A Comprehensive Review on the Drug: Fenofibrate, Int. J. Res. Pharm. Sci., 12, pp. 2164-2172, (2021)
[5] Arakawa R., Tamehiro N., Nishimaki-Mogami T., Ueda K., Yokoyama S., Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor-Dependent Manner, Arterioscler. Thromb. Vasc. Biol., 25, pp. 1193-1197, (2005)
[6] Fruchart J.C., Duriez P., Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism, Drug. Today, 42, pp. 39-64, (2006)
[7] Toth P.P., Potter D., Ming E.E., Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006, J. Clin. Lipidol., 6, pp. 325-330, (2012)
[8] Munoz A., Guichard J.P., Reginault P., Micronised fenofibrate, Atherosclerosis, 110, pp. S45-S48, (1994)
[9] Yousaf A.M., Kim D.W., Oh Y.K., Yong C.S., Kim J.O., Choi H.G., Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation, Int. J. Nanomed., 10, pp. 1819-1830, (2015)
[10] Malamatari M., Somavarapu S., Taylor K.M.G., Buckton G., Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders, Expert Opin. Drug Del., 13, pp. 435-450, (2016)

← 1 2 3 4 5 6 7 8 9 →